Hydroxyurea is the most widely prescribed cytoreductive drug for polycythemia vera because it reliably curbs the overproduction of red blood cells, white blood cells, and platelets that defines the disease, and that overproduction is what makes polycythemia vera dangerous. By slowing down the bone marrow’s output, hydroxyurea helps keep hematocrit below a critical threshold and reduces the risk of blood clots, which are the leading cause of serious complications and death in people with this condition. The drug is cheap, taken by mouth, and has decades of clinical data behind it, yet it also has real limitations that explain why newer therapies are gaining ground.
What Drives Polycythemia Vera
Polycythemia vera is a blood cancer, though it behaves differently from the cancers most people picture. The bone marrow churns out far too many red blood cells, and often too many white blood cells and platelets as well. The blood becomes thicker than it should be, which raises the risk of heart attacks, strokes, deep-vein thrombosis, and other clotting events.
In nearly all cases the underlying cause is a single genetic mutation in the JAK2 gene, most often a change known as V617F. This mutation shows up in roughly 97 to 98 percent of patients with polycythemia vera.1PubMed Central. Genetic Background of Polycythemia Vera2memo – Magazine of European Medical Oncology. JAK2 mutations in polycythemia vera: from molecular origins to inflammatory pathways and clinical implications The mutation creates a permanently “on” signal through a pathway that tells the bone marrow to keep making blood cells, even when the body already has far more than it needs. That constant overproduction is what every treatment for polycythemia vera tries to manage.
How Hydroxyurea Slows the Bone Marrow
Hydroxyurea works by blocking an enzyme called ribonucleotide reductase, which cells need to build the raw materials for new DNA. Without those materials, a cell that is trying to divide cannot copy its genetic instructions and either stalls or dies. Because the fastest-dividing cells in the body are the most affected, bone marrow cells that are rapidly producing red blood cells, white blood cells, and platelets bear the brunt of the drug’s effect.3PubMed. Mechanism of action of hydroxyurea The drug is absorbed well after a single oral dose and begins to pull blood counts down within days to weeks. In an early study of 118 patients, over 80 percent achieved control of their hematocrit and platelet count within the first 12 weeks of treatment.4PubMed. Treatment of polycythemia vera with hydroxyurea
This mechanism is broad rather than targeted. Hydroxyurea does not specifically attack the JAK2-mutated cells; it slows all rapidly dividing cells somewhat indiscriminately. That bluntness is both a strength and a weakness. It reliably reduces blood counts across the board, but it also explains most of the drug’s side effects and its inability to shrink the underlying mutant clone, a limitation discussed later in this article.
Why Hematocrit Below 45 Percent Matters
The single most important treatment goal in polycythemia vera is keeping the hematocrit, the percentage of blood volume occupied by red blood cells, below 45 percent. This target comes from a landmark randomized trial that assigned 365 patients to either a strict hematocrit goal below 45 percent or a more relaxed goal of 45 to 50 percent. The lower-target group had significantly fewer cardiovascular events and deaths from cardiovascular causes.5PubMed. Cardiovascular events and intensity of treatment in polycythemia vera That study used a combination of phlebotomy and hydroxyurea to hit the target, and it cemented the below-45-percent rule that guides treatment today.
Phlebotomy, the simple removal of blood to thin it out, can achieve this goal on its own in early or low-risk disease. But in higher-risk patients, or in anyone whose counts are hard to control with blood draws alone, hydroxyurea is added because it actively suppresses the marrow’s output and makes the target easier to maintain. Research has confirmed that in patients on hydroxyurea, keeping the hematocrit below 45 percent is associated with fewer clotting events regardless of whether occasional phlebotomies are still needed alongside the drug.6PubMed Central. Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea
Beyond Red Blood Cells: White Cells and Clotting Risk
Hydroxyurea’s value in polycythemia vera goes beyond just lowering the hematocrit. Elevated white blood cell counts are themselves a risk factor for clotting. Studies have found that white cell counts above about 11,000 per microliter significantly predict future thrombosis in polycythemia vera patients, and counts above 15,000 are associated with a higher probability of both vascular events and reduced survival.7PubMed Central. Exploring thromboembolic risk factors in polycythemia vera: from current evidence to PROSPERO study design Very high white cell counts, above 25,000, have been identified as one of the strongest pre-treatment risk factors for clotting events in real-world data as well.8PubMed. Risk of Thromboembolic Events in Patients With Polycythemia Vera: A Real-World Observational Study
Phlebotomy does nothing to address elevated white cells or platelets. Hydroxyurea, because it broadly suppresses marrow activity, pulls all three cell lines toward normal. That triple effect is a major reason it became the go-to cytoreductive therapy. In fact, research evaluating response to hydroxyurea found that bringing platelet and white blood cell counts under control was actually a better predictor of fewer clotting and bleeding complications than hematocrit response alone.9PubMed. Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera
Does Hydroxyurea Actually Prevent Blood Clots
The evidence for thrombosis prevention is strong but comes with some nuance. A large claims-database study tracked annualized thrombotic event rates before and after patients started hydroxyurea. In the cohort that stayed on hydroxyurea alone, the rate dropped from about 8.7 events per 100 patients per year before treatment to 5.6 during the initial treatment period, a meaningful reduction. However, in longer follow-up the rate appeared to rebound, climbing back toward 10.5 per 100 patients per year.10PubMed Central. Identifying Patients with Polycythemia Vera at Risk of Thrombosis after Hydroxyurea Initiation: The Polycythemia Vera—Advanced Integrated Models (PV-AIM) Project That rebound suggests that hydroxyurea’s protection may wane over time, or that the patients who remain on monotherapy for years tend to be harder to control.
When compared head-to-head with phlebotomy alone, the overall five-year rates of thrombosis were similar between the two strategies in one analysis, with roughly 6 to 7 percent of phlebotomy patients and about 5 to 6 percent of hydroxyurea patients experiencing a clotting event, a difference that was not statistically significant. The practical takeaway is that hydroxyurea’s main clinical advantage over phlebotomy alone lies in convenience, in controlling white cells and platelets, and in managing patients who cannot tolerate frequent blood draws rather than in a dramatic difference in clot rates by itself.
The Leukemia Debate
For decades, one of the biggest worries about hydroxyurea in polycythemia vera has been whether it causes leukemia. Polycythemia vera already carries an inherent risk of transforming into acute myeloid leukemia or myelodysplastic syndromes over time, so disentangling the drug’s contribution from the disease’s own tendency is difficult. The best available evidence is reassuring. A large case-control study examined the odds of leukemia across different cumulative doses of hydroxyurea and found no statistically significant increase at any dose level, even in patients who had taken more than a kilogram of the drug over their lifetime.11PubMed Central. Treatment-Related Risk Factors for Transformation to Acute Myeloid Leukemia and Myelodysplastic Syndromes in Myeloproliferative Neoplasms By contrast, older agents such as radioactive phosphorus and alkylating chemotherapy drugs showed clearly elevated leukemia risk at higher doses, with odds ratios of roughly 4.6 and 3.4, respectively.12Blood. Hydroxyurea’s Leukemogenicity in Myeloproliferative Neoplasms: A Not Guilty Verdict
That said, individual case reports continue to appear describing patients who transform to leukemia after years on hydroxyurea, and clinicians agree that ongoing monitoring is essential.13Hematology, Transfusion and Cell Therapy. Progression of Polycythemia Vera to Acute Myeloid Leukemia Following Long-Term Hydroxyurea Therapy: A Case Study The consensus view is that hydroxyurea as a single agent does not meaningfully increase leukemia risk above what the disease itself carries. The real danger lies in combining multiple cytoreductive agents over a patient’s lifetime, which roughly triples the odds of leukemic transformation.
Side Effects and Intolerance
Hydroxyurea is generally well tolerated, but a meaningful minority of patients run into problems. The most common side effects are skin-related: dry skin, darkened nails, and hyperpigmentation. Leg ulcers are an uncommon but well-known complication, particularly in older patients on long-term therapy.14PubMed Central. A Hydroxyurea-induced Leg Ulcer Because the drug works by suppressing marrow function, blood counts can drop too low, causing anemia, low white cells, or low platelets. In the early clinical experience, those drops tended to be transient and appeared within the first couple of months.4PubMed. Treatment of polycythemia vera with hydroxyurea
Formal criteria developed by the European LeukemiaNet define what counts as resistance (the drug is no longer controlling counts at adequate doses) and intolerance (the side effects are unacceptable). In one retrospective study, about 16 percent of patients were intolerant, while resistance rates ranged from roughly 5 to 24 percent depending on which version of the criteria was applied.15PubMed. Polycythemia vera and hydroxyurea resistance/intolerance: a monocentric retrospective analysis Resistance to hydroxyurea carries real consequences: one study found it was associated with roughly a five- to seven-fold higher risk of death and disease transformation compared to patients who maintained a good response.9PubMed. Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera Identifying resistance early matters because it should trigger a switch to a different therapy rather than dose escalation that yields diminishing returns.
What Hydroxyurea Cannot Do
For all its practical benefits, hydroxyurea does not address the root cause of polycythemia vera. Multiple studies have shown that the drug does not meaningfully reduce the JAK2 V617F allele burden, which is a measure of how large the mutant cell population is in the bone marrow.16PubMed Central. Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemia17PubMed Central. Hydroxyurea dose impacts hematologic parameters in polycythemia vera and essential thrombocythemia but does not appreciably affect JAK2-V617F allele burden Even at higher doses, it changes the blood counts without shrinking the clone of abnormal cells that produces them. This means hydroxyurea is managing symptoms and consequences rather than modifying the underlying disease biology.
This limitation also shows up in quality-of-life data. A large U.S. survey of polycythemia vera patients found that people on standard treatments, including hydroxyurea, still experienced burdensome symptoms and reduced quality of life. Patients who had discontinued hydroxyurea reported an even greater disease burden, possibly because they had lost even that incomplete symptom control without adequate alternatives.18Blood. Hydroxyurea Treatment History and Quality of Life in Patients with Polycythemia Vera: Results from the MPN Landmark Survey in the United States In a clinical trial comparing hydroxyurea to pegylated interferon, patients on hydroxyurea who started with high symptom burdens did see improvement, but those who started with low symptom burdens actually got slightly worse over 12 months.19The Lancet Haematology. Symptom burden and quality of life in patients with essential thrombocythaemia or polycythaemia vera treated with pegylated interferon alfa-2a versus hydroxyurea (MPN-RC 112)
Alternatives When Hydroxyurea Stops Working
When patients become resistant or intolerant to hydroxyurea, two main alternatives exist. Ruxolitinib, a JAK1/JAK2 inhibitor, directly targets the overactive signaling pathway that drives the disease. In a pivotal trial of patients who had failed or could not tolerate hydroxyurea, ruxolitinib achieved hematocrit control in 60 percent of patients compared to 20 percent on standard therapy, and produced clinically meaningful reductions in spleen size and symptoms like itching, night sweats, and bone pain.20PubMed Central. Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera A smaller phase 2 study was even more striking: 97 percent of hydroxyurea-refractory patients achieved hematocrit below 45 percent on ruxolitinib by 24 weeks.21PubMed Central. A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea
The other major alternative is pegylated interferon alfa, specifically ropeginterferon alfa-2b, which has been studied as both a first-line option and a competitor to hydroxyurea. In the PROUD-PV and CONTINUATION-PV trials, ropeginterferon and hydroxyurea performed similarly in the first year, but by 36 months ropeginterferon pulled ahead: about 53 percent of interferon-treated patients achieved a complete response with improved disease burden, compared to 38 percent on hydroxyurea.22PubMed. Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV) Unlike hydroxyurea, interferon can actually reduce the JAK2 mutant allele burden over time, raising the possibility of disease modification rather than mere symptom management. This is a distinction that increasingly matters to patients and physicians planning long-term strategy, especially in younger patients who will be on treatment for decades.
Pregnancy and Hydroxyurea
One absolute contraindication worth knowing about is pregnancy. Hydroxyurea is considered teratogenic and is not used in pregnant women with polycythemia vera.23Clinical and Experimental Obstetrics & Gynecology. Polycythemia Vera in Pregnancy: A Descriptive Review of the Literature24PubMed. Treatment options and pregnancy management for patients with PV and ET Women of childbearing age who are planning pregnancy need to be switched off the drug well in advance. Interferon alfa is the preferred cytoreductive option during pregnancy, though the management of polycythemia vera in pregnancy is complex and typically handled by a specialist team. Phlebotomy and low-dose aspirin remain the backbone of treatment during gestation, with interferon added if blood counts require more aggressive control.
Why Hydroxyurea Remains First-Line Despite Its Limits
Given its inability to modify the disease at a molecular level, its side-effect profile, and the existence of newer drugs, you might wonder why hydroxyurea still dominates treatment guidelines. Several practical factors keep it in that position. It has the longest track record of any cytoreductive agent for polycythemia vera, with prospective data stretching back more than 30 years. It is inexpensive and available worldwide, whereas ruxolitinib is costly and interferon is both expensive and requires injections. The leukemia safety data, while not perfectly reassuring, is more favorable for hydroxyurea than for nearly every other myelosuppressive agent that has been tried historically.11PubMed Central. Treatment-Related Risk Factors for Transformation to Acute Myeloid Leukemia and Myelodysplastic Syndromes in Myeloproliferative Neoplasms And for most patients, it works: blood counts come under control, clotting risk goes down, and the drug is easy to take every day.
The landscape is shifting, though. Ropeginterferon’s growing body of evidence as a first-line option and ruxolitinib’s strong results in the second-line setting mean that hydroxyurea’s role may narrow in the coming years. For now, it remains the drug most patients with polycythemia vera will encounter first, and understanding both what it does well and where it falls short is essential for making informed decisions about long-term care.